CA2294764A1 - Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins - Google Patents

Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins Download PDF

Info

Publication number
CA2294764A1
CA2294764A1 CA002294764A CA2294764A CA2294764A1 CA 2294764 A1 CA2294764 A1 CA 2294764A1 CA 002294764 A CA002294764 A CA 002294764A CA 2294764 A CA2294764 A CA 2294764A CA 2294764 A1 CA2294764 A1 CA 2294764A1
Authority
CA
Canada
Prior art keywords
hsf
pharmaceutically acceptable
mixtures
acceptable derivatives
corresponding pharmaceutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002294764A
Other languages
English (en)
French (fr)
Inventor
Maria Gabriella Santoro
Antonio Rossi
Giuliano Elia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Consiglio Nazionale delle Richerche CNR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale delle Richerche CNR filed Critical Consiglio Nazionale delle Richerche CNR
Publication of CA2294764A1 publication Critical patent/CA2294764A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002294764A 1997-07-01 1998-07-01 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins Abandoned CA2294764A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM97A000392 1996-01-14
IT97RM000392A IT1293069B1 (it) 1997-07-01 1997-07-01 Inibitori di nf-kb come attivatori di hsf e induttori di proteine da shock termico
PCT/EP1998/004066 WO1999001117A2 (en) 1997-07-01 1998-07-01 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins

Publications (1)

Publication Number Publication Date
CA2294764A1 true CA2294764A1 (en) 1999-01-14

Family

ID=11405151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002294764A Abandoned CA2294764A1 (en) 1997-07-01 1998-07-01 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins

Country Status (6)

Country Link
EP (1) EP1003492A2 (enExample)
JP (1) JP2002507981A (enExample)
AU (1) AU8854598A (enExample)
CA (1) CA2294764A1 (enExample)
IT (1) IT1293069B1 (enExample)
WO (1) WO1999001117A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289250B1 (it) 1996-12-13 1998-09-29 Consiglio Nazionale Ricerche Impiego di 2 ciclopenten 1-one e suoi derivati come inibitori del fattore nf-kb
JP2003089636A (ja) * 2001-07-12 2003-03-28 Hirofumi Kai 熱ショック蛋白質の合成抑制及び機能抑制剤
JP5697879B2 (ja) * 2010-03-12 2015-04-08 株式会社再春館製薬所 熱ショックタンパク質の発現誘導剤
JP2015042675A (ja) * 2014-11-13 2015-03-05 株式会社再春館製薬所 熱ショックタンパク質の発現誘導剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954519A (en) * 1987-04-28 1990-09-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen

Also Published As

Publication number Publication date
AU8854598A (en) 1999-01-25
WO1999001117A3 (en) 1999-04-01
JP2002507981A (ja) 2002-03-12
WO1999001117A2 (en) 1999-01-14
IT1293069B1 (it) 1999-02-11
ITRM970392A0 (enExample) 1997-07-01
ITRM970392A1 (it) 1999-01-01
EP1003492A2 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
Pahl et al. Expression of influenza virus hemagglutinin activates transcription factor NF-kappa B
Archin et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid
Umansky et al. Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-κB
US12440525B2 (en) Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
JP2004505891A (ja) ＤＮＡウイルス及びＲＮＡウイルスに対する薬品の生産における、Ｒａｆ／ＭＥＫ／ＥＲＫシグナル伝達連鎖に対して連鎖阻害剤として作用する物質の応用
US20110060050A1 (en) Sgk1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas
JP4589118B2 (ja) インフルエンザウイルス感染の治療に有用な医薬の調製のためのリスベラトロールの使用
KR20010031762A (ko) 유전자요법을 위한 과열 유도 발현 벡터 및 그의 이용 방법
CA2274108C (en) 2-cyclopenten-1-one and its derivatives as inhibitors of the nf-kb factor
CA2294764A1 (en) Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins
EP0939625B1 (en) 2-cyclopenten-1-one as an inducer of hsp70
Pica et al. Inhibition of vesicular stomatitis virus replication by Δ12-prostaglandin J2 is regulated at two separate levels and is associated with induction of stress protein synthesis
JP2002539264A (ja) 化合物とその使用
Mastromarino et al. Inhibition of Sindbis virus replication by cyclopentenone prostaglandins: a cell-mediated event associated with heat-shock protein synthesis
Balaraman et al. Leishmania donovani induces interferon regulatory factor in murine macrophages: a host defense response
US8957108B2 (en) Use of 5,6-dimethylxanthenone-4-acetic acid as an antiviral agent
Rood et al. Serum protease inhibitor abrogation of Newcastle disease virus enhancement of cytolysis by recombinant tumor necrosis factors alpha and beta
de Marco et al. Induction of the heat‐shock response by antiviral prostaglandins in human cells infected with human immunodeficiency virus type 1
Sano et al. Nitric oxide releasing reagent, S‐nitroso‐N‐acetylpenicillamine, enhances the expression of manganese superoxide dismutase mRNA in rat vascular smooth muscle cells
CN111329858B (zh) 一种小分子抑制剂在抑制病毒沉默抑制蛋白中的应用
JP2005511791A (ja) 医薬組成物の改良
US20050020687A1 (en) Methods of treating inflammatory and viral disorders by administering cyclopentenone compounds
JPH0383933A (ja) サイトカインの内在及び／又は産生に関係する疾患状態の治療に使用する薬剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued